Frontlight ResearchEarly access
Taking people in United StatesPhase 4
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
Key facts
- Who runs it
- Bassett Healthcare
- Where
- Charleston, Cooperstown, Flushing, Morgantown, Omaha, Winston-Salem, and Worcester, United StatesSee the 7 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 852 people, planned
- Started
- 17 Aug 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Piperacillin + Tazobactam
- meropenem
- Record updated
- 15 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Hospitalized or being hospitalized
- Age >/=18 yr old
- Serious or suspected serious infection for which VPT or VM considered a broad-spectrum combination antibiotic backbone standard of care by clinician
- Enrollment can be completed before the first dose of abx (ideally) and no later than before the second dose (alternatively)
- Consenting/enrollment will not clinically significantly delay abx administration
- Baseline and >/=1 prior Scr available (within 1 yr)
- Pt or LAR able to provide IC. Exclusion criteria
- AKI (>/=moderate) (KDIGO stage 2-3) (Scr increase >/=2-fold from chronic BL) (Scr based)
- CKD (>/=moderately to severely decreased eGFR) (KDIGO stage G3b-G5) (by history or eGFR </=44 mL/min/1.73M2) (Scr based)
- Beta lactam allergy. 4. Contraindication to VPT or VM. 5. Infection requiring VPT or VM specifically or another abx regimen. 6. Participation in another research study with interventions that may impact study endpoints
Where in United States
- Medical University of South Carolina - South Carolina Clinical & Translational Research InstituteCharleston, United StatesContact: Della MacNicholasTaking people
- Bassett Medical CenterCooperstown, United StatesContact: Jennifer VictoryTaking people
- NY Presbyterian/QueensFlushing, United StatesContact: Helen VargheseNot yet recruiting
- West Virginia UniversityMorgantown, United StatesContact: Karen HunterTaking people
- University of Nebraska Medical CenterOmaha, United StatesContact: Brooklin ZimmermanTaking people
- Wake Forest University Health SciencesWinston-Salem, United StatesContact: Karen Ayala BaylonTaking people
- University of Massachusetts Chan Medical SchoolWorcester, United StatesContact: Melissa AdamsNot yet recruiting
About the trial
What the trial wants to find out
The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.
The 2 groups in the trial
- Piperacillin/tazobactamExisting treatment, for comparison
Vancomycin plus piperacillin/tazobactam
- MeropenemExisting treatment, for comparison
Vancomycin plus meropenem
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin/Tazobactam or Meropenem: VPT Patient Safety (VPS) Study
- Record updated
- 15 October 2026